Intro

This chapter explores the latest developments in weight loss medications, particularly focusing on semaglutide and terzipatide alongside a new triple agonist. The discussion also covers Novo Nordisk's stock fluctuations and the competitive dynamics within the pharmaceutical industry impacting clinical practices and patient care.